DOJ corporate fraud directive expands healthcare program-integrity targeting signals
Oct 11, 2026 edition · GC-2026-0214 · Published 2026-10-11 · Version 3 · Announced
DOJ pairs corporate-enforcement principles with an October 7 directive on cross-cutting fraud methods. Healthcare is expressly included, while these prosecutor instructions create no new provider filing deadline.
What happened
Directive 26-12, dated October 1, identifies healthcare among corporate fraud priorities and directs prosecutors to apply established corporate-prosecution and voluntary-disclosure policies. It emphasizes accountability while guarding against overbroad enforcement and crediting disclosure, cooperation, and remediation. That context matters when evaluating the later methods directive; neither document establishes that a particular healthcare organization committed misconduct.
Directive 26-13 directs assessment of appropriate tax, securities, consumer, and other charges alongside fraud theories. It emphasizes early recovery of proceeds and legally available injunctions or seizures, including digital infrastructure used in schemes. Its guidance applies to prosecutors and disclaims creation of enforceable private rights. Compliance preservation and affiliate-control review are internal readiness recommendations, rather than new statutory duties or proof that a specific provider faces investigation.
Scope and timing
- Authority status
- Announced
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
- Affected functions
- Compliance, Legal, Executive Leadership, Revenue Cycle
- Responsible owner
- Compliance
Why it matters
The directive expressly includes healthcare fraud and instructs prosecutors on tax, securities and consumer charges. It governs prosecutor methods; it establishes no new provider implementation deadline.
Recommended action
Counsel and compliance should align preservation, billing-integrity and affiliate controls with potential cross-program investigations. These are recommended internal readiness steps.
Implementation playbook
- Brief compliance leadership on the corporate fraud priorities and escalation triggers. Compliance · Due 2026-10-18
- Reconcile billing-outlier monitoring with clinical and enrollment controls. Legal · Due 2026-10-18
- Review existing resolution requirements and voluntary-disclosure considerations with counsel, without treating the DOJ internal seven-day deadline as a provider duty. Executive Leadership · Due 2026-10-18
Sources
- DOJ corporate enforcement priorities memorandumOfficial · U.S. Department of Justice · 2026-10-01 · Source review 2026-10-05
- Directive 26-13, seven-page memorandumOfficial · DOJ · 2026-10-07 · Source review 2026-10-11
- Directive 26-13, A Comprehensive Approach in the Fight Against Fraud, official clean PDF URLOfficial · U.S. Department of Justice · 2026-10-07 · Source review 2026-10-14
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Medicare & Medicaid report →